Researchers said the drugs don’t appear to raise the risk of suicidal thoughts or actions for young people but also urged ...
Allowing Medicare to cover anti-obesity medications would drive up federal spending by about $35 billion on net between 2026 and 2034, according to ...
The cost of taking weekly injections of popular anti-obesity medications liraglutide (Saxenda) or semaglutide (Wegovy) ...
An obesity expert weighs in on intriguing new data and new drugs that hold promise in the battle against a stubborn problem.
Still, more than a quarter of employers are considering adding coverage for GLP-1 drugs for weight loss in 2025 or 2026, ...
France is the latest European country to refuse to cover weight loss drugs through its national insurance programme.View on ...
The report shows a rise in medication use, obesity, and smoking, a decline in cancer screenings, concerns over excessive ...
Medicare coverage of weight loss drugs, if authorized, is seen increasing federal spending by about $35B from 2026 to 2034.
That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...
Covering weight-loss drugs for elderly Americans on the state-backed Medicare health insurance programme would cost the US government $35bn over the next nine years, a congressional analysis has found ...
Hoping your company will begin paying for anti-obesity medications like Wegovy? You may be in luck. A growing number of employers are considering covering the blockbuster weight-loss drugs ...